Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib for FGFR-altered advanced solid tumors (China, multicenter observational study)
ChiCTR2300071619Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pemigatinib in Non-hematologic malignancy, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective response rate. Planned start May 2023; status: not yet recruiting.
02
Drugs
pemigatinib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2300071619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071619.